Last reviewed · How we verify

Botox infiltration

University Rovira i Virgili · FDA-approved active Small molecule

Botulinum toxin blocks acetylcholine release at the neuromuscular junction, causing temporary paralysis of injected muscles.

Botulinum toxin blocks acetylcholine release at the neuromuscular junction, causing temporary paralysis of injected muscles. Used for Muscle hyperactivity disorders (cervical dystonia, blepharospasm, hemifacial spasm), Chronic migraine, Spasticity.

At a glance

Generic nameBotox infiltration
Also known asbotox infiltration, and grup solving terapy group
SponsorUniversity Rovira i Virgili
Drug classNeurotoxin; botulinum toxin type A
TargetSNARE complex (synaptosome-associated protein); acetylcholine release machinery
ModalitySmall molecule
Therapeutic areaNeurology; Dermatology; Aesthetics
PhaseFDA-approved

Mechanism of action

Botox (botulinum toxin type A) cleaves SNARE proteins required for acetylcholine vesicle release, preventing muscle contraction in the infiltrated area. This results in temporary muscle relaxation lasting 3-4 months. The effect is localized to the injection site and gradually reverses as new neuromuscular junctions form.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results